RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 12.0656

Change

-0.57 (-4.54)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-12 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

-1.43 (-3.27%)

USD 1.42B
PSQ ProShares Short QQQ

-1.53 (-4.00%)

USD 0.67B
SPXU ProShares UltraPro Short S&P50..

-2.20 (-9.84%)

USD 0.52B
SOXS Direxion Daily Semiconductor B..

-3.46 (-21.63%)

USD 0.46B
YANG Direxion Daily FTSE China Bear..

-3.80 (-9.93%)

USD 0.27B
SDOW ProShares UltraPro Short Dow30

-4.32 (-8.44%)

USD 0.23B
RWM ProShares Short Russell2000

-0.71 (-3.48%)

USD 0.21B
FNGD MicroSectors FANG+ Index -3X I..

-1.45 (-13.38%)

USD 0.18B
SPDN Direxion Daily S&P 500® Bear ..

-0.37 (-3.26%)

USD 0.18B
DOG ProShares Short Dow30

-0.78 (-2.85%)

USD 0.14B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.39% 85% B 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.39% 85% B 62% D
Trailing 12 Months  
Capital Gain 9.99% 96% N/A 73% C
Dividend Return 2.66% 60% D- 49% F
Total Return 12.66% 96% N/A 73% C
Trailing 5 Years  
Capital Gain -57.44% 85% B 6% D-
Dividend Return 3.09% 77% C+ 6% D-
Total Return -54.36% 84% B 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 67.10% 39% F 96% N/A
Dividend Return 68.58% 39% F 96% N/A
Total Return 1.48% 58% F 35% F
Risk Return Profile  
Volatility (Standard Deviation) 432.91% 63% D 3% F
Risk Adjusted Return 15.84% 52% F 34% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.